Hilary Wilkinson, Ph. D
Senior Director of Biology at Eternity Bioscience Inc., Cranbury, New Jersey
Dr. Hilary Wilkinson obtained her bachelor degree in life science from MIT and got her Ph. D degree in molecular biology from Princeton University. After completing two year postdoctoral research work on ivermectin related project at Merck, Dr. Wilkinson joined Merck Research Laboratory in Rahway where she totally spent 19 years. During her tenure at Merck, she quickly advanced her career with more and more responsibilities from a scientist to project leader and a director, leading multiple project teams. She contributed to the advancement of eight clinical candidates and sit in the early development team (EDT) overseeing the clinical trial design. She experienced in developing the franchise strategy regarding clinical, basic research, regulatory and marketing approaches to support drug development. She led in vitro and in vivo assay development teams and managed strategic collaborations with scientific groups cross functions internally and externally. Hilary briefly stayed as a research scientist in Rutgers University in 2013 before joining CHDI, a non-profit organization focusing on searching therapies for Huntington’s diseases. Hilary served as the scientific director in charge of multiple research programs involving mechanism studies of molecular machines and therapeutic agent discovery program for Huntington’s disease in collaboration with academic and CROs. Hilary is an expert in drug discovery targeting oncology, bone, muscle and central nervous system indications with multiple therapeutic modalities and varied delivery approaches (inhaled, transdermal and oral). Based on her research work during academic and industry, Hilary published over 35 peer-reviewed papers.
Dr. Wilkinson joined Eternity Bioscience, Inc. as the senior director leading biology department in February 2021.